TLSI - NASDAQ

TriSalus Life Sciences, Inc.

TLSI·NASDAQ

$3.29

+3.0%

HealthcareMedical - Devices

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$124.72M

EPS-1.8400

P/E Ratio-1.79

Earnings Date08/11/2026

tlsi

Net Cash Provided by Investing Activities

Last Annual Value

-838.00K

3-Year CAGR

22%

5-Year CAGR

68%

10-Year CAGR

43%

Adjust for Inflation

TriSalus Life Sciences, Inc. Competitors Analysis of Net Cash Provided by Investing Activities

TLSI · NASDAQ

Company	Net Cash Provided by Investing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
TriSalus Life Sciences, Inc. NASDAQ:TLSI	-838.00K	N/A	N/A	N/A
MaxCyte, Inc. NASDAQ:MXCT	25.93M	-22.2%	N/A	N/A
Forte Biosciences, Inc. NASDAQ:FBRX	36.23M	816.9%	N/A	4.0%
Sight Sciences, Inc. NASDAQ:SGHT	-224.00K	N/A	N/A	N/A
Hyperfine, Inc. NASDAQ:HYPR	-1.19M	N/A	N/A	N/A
AVITA Medical, Inc. NASDAQ:RCEL	12.45M	97.9%	N/A	N/A
Rapid Micro Biosystems, Inc. NASDAQ:RPID	14.33M	-30.2%	N/A	N/A
LENSAR, Inc. NASDAQ:LNSR	1.28M	N/A	N/A	N/A
Perspective Therapeutics, Inc. AMEX:CATX	41.23M	19.2%	N/A	39.2%
Neuronetics, Inc. NASDAQ:STIM	-801.00K	N/A	N/A	N/A
Armata Pharmaceuticals, Inc. AMEX:ARMP	-542.00K	N/A	N/A	N/A

TriSalus Life Sciences, Inc. Fair Value Envelope

TLSI · NASDAQ

Our analysis suggests that TLSI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.29, this represents a potential HIDDEN relative to our calculated worth for TriSalus Life Sciences, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.29

Related Guides

Blog Categories

Continue your TLSI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.